Nature Medicine
Nature Medicine is Nature's clinical journal and now a top venue for early-phase and biomarker-rich cancer trials, medical AI studies and cell-therapy reports.
Nature Medicine appears monthly and publishes phase 1 and 2 trials with deep translational analysis (MagnetisMM-3 elranatamab in this corpus), circulating tumour DNA and multi-cancer early-detection studies, large medical-AI validations and consensus reporting guidelines for AI in medicine. Hybrid access with a Springer Nature open-access option.
CEPHEUS extends the quadruplet standard to patients who are not going to transplant, closing the gap between transplant-eligible and ineligible populations. It is also one of the first phase 3 trials to be designed around MRD-negativity as the primary endpoint, which could shorten future myeloma trials by years. Frailer patients still need dose-adapted approaches.
The blood test stratifies risk far better than stage or pathology. It supports treating ctDNA-positive patients and suggests ctDNA-negative patients gain little from chemotherapy, but because treatment was not randomised the de-escalation claim needs the randomised trials that are now under way.
Elranatamab confirmed that BCMA bispecifics are a class, not a one-off, and its protocol-built dose reduction after response set a precedent for lowering the immunosuppressive burden of T-cell engagers. Patients now have two approved BCMA bispecifics and one against GPRC5D (talquetamab). Choosing between them, and sequencing them with CAR-T, remains guided by availability and toxicity profile rather than head-to-head data.
Led OlympiA, the trial that showed a year of olaparib after surgery improves survival in BRCA-mutated breast cancer.
Co-invented the CAPP-Seq method for reading tumour DNA in blood and used it to track lymphoma and lung cancer.
Built small-cell lung cancer models from circulating tumour cells and leads the Manchester institute.
First author of the CT041 trials that showed a CAR-T can shrink gastric and pancreatic tumours.
Engineered the IL13Rα2 CAR-T cells that produced a complete response in glioblastoma when infused into the brain.
Built MSK-IMPACT, the first FDA-authorised tumour sequencing panel, and the clinical genomics programme behind OncoKB and cBioPortal.
Discovered cancer stem cells, showing leukaemia is driven by a rare population of self-renewing cells.
Developed in situ vaccination, turning a single injected lymphoma tumour into a vaccine against the rest.
Led the CT041 trials that produced the first CAR-T therapy approved for a solid tumour, in gastric cancer.
Min-Hee Ryu is a gastric cancer and GIST trialist central to the Asian arms of ramucirumab, pembrolizumab, and zolbetuximab studies.
Nirali Shah developed CD22 CAR-T for children whose leukaemia escaped CD19 therapy.
Immunologist who spent four decades engineering T cells to attack leukaemia and solid tumours.
Genomics leader behind LC-SCRUM-Japan, the nationwide screening network that finds rare lung cancer drivers for trials.
Leads CIRCULATE-Japan, the largest ctDNA-guided adjuvant programme in colorectal cancer, and the PARADIGM and SCRUM-Japan GI efforts.
Ran the first clinical trial of CRISPR-edited T cells in humans, in patients with lung cancer.